Atea Pharmaceuticals Inc (AVIR)
$3.7
Insights on Atea Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 37.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 330.5%
Performance
- $3.68$3.73$3.70
0.54%
Downside
Day's Volatility :1.34%
Upside
0.8%
- $2.77$5.19$3.70
25.14%
Downside
52 Weeks Volatility :46.63%
Upside
28.71%
Returns
| Period | Atea Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.86% | 1.7% | 0.0% |
6 Months | 25.0% | 11.3% | 0.0% |
1 Year | 12.46% | 5.4% | 1.3% |
3 Years | -89.85% | 13.9% | -22.1% |
Highlights
Market Capitalization | 313.9M |
Book Value | $6.65 |
Earnings Per Share (EPS) | -1.63 |
Wall Street Target Price | 3.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -11.89% |
Return On Equity TTM | -22.74% |
Revenue TTM | 192.2M |
Revenue Per Share TTM | 2.31 |
Quarterly Revenue Growth YOY | 295.2% |
Gross Profit TTM | -81.9M |
EBITDA | -119.6M |
Diluted Eps TTM | -1.63 |
Quarterly Earnings Growth YOY | 2.64 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -2.92 |
EPS Estimate Current Quarter | -0.5 |
EPS Estimate Next Quarter | -0.61 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 5.41%
Technicals Summary
Sell
Neutral
Buy
Atea Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atea Pharmaceuticals Inc | -3.14% | 25.0% | 12.46% | -89.85% | -87.8% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atea Pharmaceuticals Inc | 11.84 | NA | NA | -2.76 | -0.23 | -0.12 | NA | 6.65 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atea Pharmaceuticals Inc | Sell | $313.9M | -87.8% | 11.84 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
BlackRock Inc
11.22%EcoR1 Capital, LLC
8.31%BML Capital Management LLC
6.49%FMR Inc
6.36%Vanguard Group Inc
5.47%TANG CAPITAL MANAGEMENT LLC
4.28%
Company Information
atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.
Organization | Atea Pharmaceuticals Inc |
Employees | 75 |
CEO | Dr. Jean-Pierre Sommadossi Ph.D. |
Industry | Health Technology |
